Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation
| Autor: | Rajat Kumar, Cassandra McEwan, Ram V Nampoothiri, Jeffrey H. Lipton, Dennis Dong Hwan Kim, Jonas Mattsson, Fotios V. Michelis, Santhosh Thyagu, Armin Gerbitz, Arjun Datt Law, Lina Ho, Wilson Lam, Auro Viswabandya, Ivan Pasic |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Eltrombopag Benzoates Graft function 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Internal medicine Humans Medicine Complete response Retrospective Studies Transplantation Hematopoietic cell business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Thrombocytopenia Treatment efficacy Hydrazines chemistry 030220 oncology & carcinogenesis Maximum dose Costs and Cost Analysis Cost analysis Pyrazoles business 030215 immunology |
| Zdroj: | Bone Marrow Transplantation. 56:2471-2476 |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | Eltrombopag has shown efficacy in the treatment of thrombocytopenia and poor graft function (PGF) after allogeneic hematopoietic cell transplantation (HCT) in retrospective observational studies, but is not approved for this indication. The cost of this drug is also a major concern in publicly funded health care systems. We collected data about patients who received eltrombopag for thrombocytopenia or PGF after HCT. Post-HCT thrombocytopenia, PGF, and eltrombopag response were defined as per previously published criteria. Primary outcome was treatment efficacy and secondary outcome was cost comparison between estimated treatment cost prior to and after initiation of eltrombopag. Seventeen patients (males 70.6%; median age = 58) received eltrombopag. Isolated thrombocytopenia was present in 11.8% (n = 2) patients while PGF was present in 88.2% (n = 15) of patients. After 8 weeks of treatment at the maximum dose of 150 mg orally daily, overall response rate (ORR) was seen in 76.5% (13/17) of patients: complete response (CR) in 10/13 patients and partial response (PR) in 3/13 patients. The use of eltrombopag was associated with an overall decrease in the total weekly care costs (5021 vs 2,524 CA$; P = 0.04). Thus, Eltrombopag is an efficacious and possibly cost-effective therapy for thrombocytopenia and PGF after allogeneic HCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink